| INTRODUCTION
Until the advent of direct-acting anti-viral agents (DAAs), the standard of care for hepatitis C virus (HCV infection) was long-term interferonbased therapy (with/without ribavirin). These regimens were associated with intolerable side effects and suboptimal sustained virologic response (SVR) rates, that is, approximately 50% in genotype 1 patients, 1, 2 and even lower in patients with severe fibrosis. 3 Treatment with DAAs, which is well tolerated, has increased SVR rates to over 90% in genotype 1 patients with/without liver cirrhosis. 4 Moreover, DAAs are administered for a much shorter time than interferon-containing regimens. 5 Hepatocellular carcinoma (HCC) is a frequent consequence of HCV-related cirrhosis, with an annual incidence between 1% and 4%. 6 Five clinical trials have evaluated the outcome of a wide range of patients affected by cirrhosis and HCC treated with DAAs. [7] [8] [9] [10] [11] Only one of these trials included HCC patients listed for liver transplant. 12 The SVR rate was low in the latter trial, which evaluated a sofosbuvir-ribavirin regimen, and virologic relapses were observed before liver transplant. The sofosbuvir-ribavirin regimen is now considered suboptimal and is no longer recommended for genotype 1 patients. 13, 14 Although DAAs are effective in the treatment of cirrhotic and noncirrhotic patients, their effect in individuals with HCC remains to be established. Recently, Prenner et al reported that active HCC at the start of DAA therapy is significantly associated with treatment failure and suggested that the tumour may serve as a viral reservoir. 15 The aim of our study was to assess whether the likelihood of achieving an SVR with DAA regimens differed between patients with cirrhosis and patients with cirrhosis and successfully treated HCC.
2 | ME TH ODS
| Patients
We analysed data prospectively collected from HCV-infected cirrhotic patients who were consecutively treated with DAAs from January to 
| Statistical analysis
Data were analysed with parametric and nonparametric tests as appropriate. The two-sample median test was used to compare continuous variables, while the Fisher's exact test was used to compare dichotomous variables. Univariable and multivariable logistic regression models were used to assess the association between patient characteristics and SVR. To account for differences of the characteristics of patients with and without previous HCC, we performed a propensity score matching study: patients with previous HCC were matched using propensity score for age, sex, aetiology, MELD score, alphafetoprotein and discontinuation of therapy with an equal number of patients without previous HCC. SVR rate in the 2 matched groups was then compared with the Fisher's exact test. All reported P-values were two-sided. Analyses were performed using SAS software, version 9.4 (SAS Institute, Cary, NC). Table 1 reports on variables associated to SVR and shows that age less than 50 years (P = 0.04), elevated MELD score (P < 0.0001), genotype 3 or 4 infection (P = 0.002), more severe varices (P = 0.008), previous bleeding (P = 0.001), severe ascites (P < 0.0001), Child class B/C (P < 0.0001), hepatic encephalopathy (P = 0.002), low platelets count (P = 0.006), elevated serum glutamic oxaloacetic transaminase (SGOT; P = 0.03), suboptimal DAA treatment (P < 0.0001) and discontinuation of therapy (P < 0.0001) were significantly associated with treatment failure (no-SVR). Reasons for discontinuation are reported in Table 2 . with SVR (OR = 0.81; 95% CI 0.37-1.77; P = 0.59).
The lack of association between a past history of HCC and SVR rate (P = 0.81) has been confirmed in a propensity score analysis in which patients with previous HCC and cirrhotic patients were matched on age, sex, aetiology, MELD score, alphafetoprotein and discontinuation of therapy (Table 4) .
| DISCUSSION
The response to DAA regimens in HCV-related chronic hepatitis ranges between 80% and 97%, irrespective of the severity of the underlying liver disease. 18 Decompensated cirrhosis and genotype 3 Information missing for few patients: Previous treatment (n = 42), varices (n = 56), hepatic encephalopathy (n = 1), previous bleeding (n = 4), class of Child (n = 6), diabetes (n = 38), DAA regimen (n = 2). infection are negative predictive factors of response. 19 Some concern was aroused by a report of a high rate of early tumour recurrence coinciding with HCV clearance in patients with HCV-related HCC undergoing DAA treatment. 20 However, it was suggested that this result was simply due to the relatively new practice of using DAAs to treat advanced liver disease rather than the harbouring of HCC foci in cirrhotic livers. 21, 22 Currently, based on a large body of evidence, these new anti-viral agents are considered useful and safe. [23] [24] [25] [26] Little is known about the efficacy of anti-viral therapy in cirrhotic patients with previous HCC. 12, 15 To address this issue we conducted a large prospective national multicentre study to compare SVR after a DAA regimen in HCV cirrhotic patients vs SVR in previous HCC cirrhotic patients treated with DAAs for 6 months after the apparent remission of the tumour. Our results show that a history of HCC did not affect the possibility of achieving a SVR. In fact, the prevalence of an SVR did not differ between the 2 groups. However, the similar SVR in our 2 cohorts is in line with Beste et al who found the same SVR values in cirrhotic and HCC patients who had undergone liver transplantation and significantly lower in active nontreated HCC patients. 27 On the other hand, Prenner et al reported that HCV antiviral therapy with DAAs in HCC patients was associated with significantly higher treatment failure compared to cirrhotic patients, irrespective of the traditional predictors of nonresponse. 15 The discrepancy between the latter finding and our data showing a similarly high SVR in the 2 groups might be related to the different timing of treatment onset. In fact, as recommended by Italian guidelines, we started DAA therapy 6 months after completion of HCC treatment, whereas Prenner et al started treatment in patients with HCC soon after completion of HCC treatment. 15 This difference between the 2 studies raises the possibility that clinically active HCC might be a negative predictor factor of response to therapy.
In the same study, Prenner et al also reported that a high prevalence of cirrhotic patients who did not respond to DAAs had clinically silent HCC at treatment onset. 15 Similarly, Fangazio et al reported a higher prevalence of nonresponse in 11/286 DAA-treated | 1709 patients in whom de novo/recurrent HCC was detected 24 weeks after completion of therapy. 28 The latter result coincides with our observation that newly diagnosed HCC in patients with cirrhosis (50/1766: 2.8%), and recurrence in previous HCC patients (38/161:
23.6%) were significantly associated to nonresponse to anti-viral therapy. These findings raise questions about when to treat HCVinfected patients with HCC in order to get the best possible SVR.
Delaying DAA treatment for at least 6 months after apparent restitution of HCC might be considered.
The pathophysiological mechanism(s) underlying the negative effect of HCC on the response to DAAs remain to be established. It is feasible that viral clearance may be impaired because, given their undifferentiated nature, neoplastic cells might alter the intake of the drug, and/or because the vascular structure of HCC might impede homogeneous distribution of the drug in neoplastic tissue.
Our data also show that liver function and/or portal hypertension affected SVR. This is in agreement with reports of a lower prevalence of SVR in decompensated cirrhosis vs patients with severe compensated disease. 11, 29 Similarly, Di Marco et al recently reported that oesophageal varices were independent predictive factors of nonresponse to interferon-based anti-viral therapy. 30 In conclusion, our data show that DAA therapy of HCV in cirrhotic patients with a history of HCC is effective, and support the concept that the benefit of this therapy in terms of viral eradication and disease progression over time outweighs the possibility that it might be related to the development of HCC. Lastly, based on our results, we suggest that DAA treatment be delayed until at least 6 months after the apparent remission of HCC in order to achieve SVR.
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